Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 17INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 7Genitourinary 7Breast 5Tumor-Agnostic 4CNS 4Other solid neoplasm 3Head & Neck 3Dermatologic 3Gynecologic 2Plasma cell 1Other hematologic neoplasm 1Other 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Melanoma 2Neoplasms 1Keratosis, Actinic 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 181Nivolumab 117Ipilimumab 97Dacarbazine 48trametinib 37dabrafenib 353-ingenyl angelate 35Vemurafenib 33cemiplimab 27atezolizumab 24Temozolomide 24binimetinib 23Paclitaxel 22Imiquimod 22encorafenib 17avelumab 17Carboplatin 17Aminolevulinic Acid 17spartalizumab 16cobimetinib 16Cyclophosphamide 15Cisplatin 15Fluorouracil 14talimogene laherparepvec 13HhAntag691 11Gels 11Drug Therapy 11Bevacizumab 11lenvatinib 10durvalumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Therapeutics × Dermatologic × Clear all
NCT07406724 2026-02-12

HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma

Qingdao Sino-Cell Biomedicine Co., Ltd.

Phase 2 Not yet recruiting
90 enrolled
Dermatologic

Melanoma

NCT07137819 2025-08-22

EXACT-1

Aresus Pharma GmbH

Phase 3 Recruiting
280 enrolled
Dermatologic

Keratosis, Actinic

NCT00827177 2014-01-24

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
87 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡